CD44 and ovarian carcinoma: As shown in Figure 5, the proliferation inhibition rate of ovarian cancer HO8910 cells treated with DDP/CD44-shRNA/MFH was (91.33 ± 0.22)%, significantly higher than (23.71 ± 0.54)% of DDP group, (43.47 ± 1.17)% of DDP/CD44-shRNA group, (59.34 ± 2.20)% of MFH group, (78.87 ± 1.06)% of CD44-shRNA/MFH group, and (84.32 ± 1.02)% of DDP/MFH group, p<0.05 (Figure 5A).